Documents

 

Inclusie voltooid!

Algemeen

Inclusie/randomisatie

Monitoring HYPITAT-II

Administratie HYPITAT-II

Neonatale follow-up (6 mnds)

Neonatale follow-up (2 jrs)


Neonatale follow-up (5 jrs)

Kwaliteit van leven

METC/Trial-register/Zon-Mw

Presentations

  • Oral presentation Oktober 2010, 17th World Congress ISSHP, Melbourne. Langenveld et al. Neonatal outcome of pregnancies complicated by hypertensive disorders between 34 and 37 weeks of gestation. Young investigator travel award.
    Powerpoint
  • Oral presentation February 2014, 34rd Pregnancy meeting, Society for Maternal-Fetal Medicine, New Orleans. Broekhuijsen et al. Immediate delivery versus expectant monitoring for women with late preterm hypertensive disorders (Hypitat-II): a randomized, open-label, controlled clinical trial. Norman F. Gant award for best research in maternal medicine, award of research excellence for best presentation in oral plenary session.
    Hypitat2 presentation results SMFM 2014
  • Oral presentation March 2014, ObNeo congress 2014, Veldhoven. Broekhuijsen et al. Direct bevallen versus expectatief beleid voor hypertensieve aandoeningen tussen 34 en 37 weken zwangerschap. (Presentation in Dutch).
    HYPITAT2 resultaten ObNeo 2014
  • Oral presentation May 2014, Congress of the Dutch Society for Obstetrics and Gynaecology, Leeuwarden. Langenveld et al. Direct bevallen versus expectatief beleid voor hypertensieve aandoeningen tussen 34 en 37 weken zwangerschap. (Presentation in Dutch).
    HYPITAT2 resultaten Gynaecongres mei 2014
  • Oral presentation June 2014, 14th European Congress of Perinatal Medicine, Florence. Broekhuijsen et al. Hypitat-II: immediate delivery versus expectant monitoring for late preterm hypertensive disorders.
    HYPITAT2 results ECPM 2014

Publications

  • Publication results in the Lancet:
    Broekhuijsen K, van Baaren GJ, van Pampus MG, Ganzevoort W, Sikkema MJ, Woiski MD, et al.
    Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled Trial.
    The Lancet. Published online March 25th, 2015.
    http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61998-X/abstract

  • Correction protocol:
    Broekhuijsen K, Langenveld J, van Baaren GJ, van Pampus MG, van Kaam AH, Groen H, et al. HYPITAT-II study group.
    Correction: Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia between 34 and 37 weeks’ gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial. (Correction protocol)
    BMC Pregnancy and Childbirth 2013, 13:232
    http://www.biomedcentral.com/1471-2393/13/232

  • Protocol:
    Langenveld J, Broekhuijsen K, van Baaren GJ, van Pampus MG, van Kaam AH, Groen H, et al. HYPITAT-II study group.
    Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia between 34 and 37 weeks' gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial. (Protocol)
    BMC Pregnancy Childbirth. 2011 Jul 7;11:50.
    http://www.biomedcentral.com/1471-2393/11/50